Global Benchmark for Efficient Drug Pricing (GLOBE) Model

HHS published a Rule for the Global Benchmark for Efficient Drug Pricing — the GLOBE Model — a Medicare payment experiment aimed at bringing U.S. drug prices closer to peer countries.

Model rules decide which drugs, which providers, and which payment math apply. Hospitals and manufacturers watch these pages the way markets watch a rate decision.

Filing abstract (agency text): This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs f…

Hospital pharmacy directors, Medicare Advantage plans, and pharma policy shops: pull the GLOBE Model rule for covered drugs and effective dates.

Federal Register filing: https://www.federalregister.gov/documents/2026/10/02/2026-20281/global-benchmark-for-efficient-drug-pricing-globe-model

This is a Notice Nearby publisher-desk Federal brief — a short in-house summary of a public federal filing. It is not official agency minutes, not a newspaper story, and not Legal Publication. It does not satisfy a statutory notice requirement.